Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck

Cancer

Volumn 92, Issue 9, 2001, Pages 2364-2373

  Tseng, Jennifer E ^a   Glisson, Bonnie S ^a   Khuri, Fadlo R ^a   Shin, Dong M ^a   Myers, Jeffrey N ^a   El Naggar, Adel K ^a   Roach, Jennifer S ^a   Ginsberg, Lawrence E ^a   Thall, Peter F ^a   Wang, Xuemei ^a   Teddy, Stephanie ^a   Lawhorn, Kristie N ^a   Zentgraf, Rebecca E ^a   Steinhaus, Ganene D ^a   Pluda, James M ^b   Abbruzzese, James L ^a   Hong, Waun Ki ^a   Herbst, Roy S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Basic fibroblast growth factor; Squamous cell carcinoma of the head and neck; Thalidomide; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; CYTOTOXIC AGENT; THALIDOMIDE; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG TOLERABILITY; FEMALE; HEAD CANCER; HUMAN; MALE; METASTASIS; NECK CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN DETERMINATION; SQUAMOUS CELL CARCINOMA; TOXICITY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 0035498677     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20011101)92:9<2364::AID-CNCR1584>3.0.CO;2-P     Document Type: Article

References (67)

1. Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses
2. Further observation with thalidomide in lepra reactions
3. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus
4. The place of thalidomide in the treatment of inflammatory disease
5. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: Experience in sixteen consecutive patients
6. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide
7. Thalidomide: Treatment of choice for aphthous ulcers in patients seropositive for human immunodeficiency virus
8. Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody
9. Thalidomide effects in Behcet's syndrome and pustular vasculitis
10. Thalidomide in the treatment of Behcet's syndrome
11. Thalidomide: Current and potential clinical applications
12. Thalidomide is an inhibitor of angiogenesis
13. Antitumor activity of thalidomide in refractory multiple myeloma
14. Activity of thalidomide in AIDS-related Kaposi's sarcoma
15. Cancer statistics, 2000
16. Head and neck cancer
17. The role of chemotherapy in the curative treatment of head and neck cancer
18. Standard chemotherapy in squamous cell head and neck cancer: What we have learned from randomized trials
19. The role of chemotherapy in head and neck cancer
20. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck
21. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma
22. Monoclonal antibody (MOAB) IMC-C225, an anti-epidermal growth factor receptor (EGFR), for patients (pts) with EGFR-positive tumors refractory to or in relapse from previous therapeutic regimens
23. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma
24. A rapid colorimetric in situ messenger RNA hybridization technique for analysis of epidermal growth factor receptor in paraffin-embedded surgical specimens of human colon carcinomas
25. A rapid colorimetric in situ mRNA hybridization technique using hyperbiotinylated oligonucleotide probes for analysis of mdrl in mouse colon carcinoma cells
26. Nonparametric estimator from incomplete observations
27. Regression models and life tables
28. Thalidomide in the management of multiple myeloma: The Arkansas experience in > 300 patients with single agent and combination chemotherapy
29. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
30. Therapy with thalidomide in refractory multiple myeloma patients - The revival of an old drug
31. Thalidomide in the treatment of relapsed multiple myeloma
32. Papadimitriou activity of thalidomide in Waldenstrom's macroglobulinemia
33. Encouraging improvement in cytopenias of patients with myelodysplastic syndromes with thalidomide
34. Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer
35. Phase II evaluation of thalidomide in patients with metastatic breast cancer
36. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
37. Phase II trial of thalidomide for treatment of nonresectable hepatocellular carcinoma
38. Thalidomide treatment of metastatic renal-cell carcinoma
39. The FDA experience on the use of thalidomide in advanced malignancies
40. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is speciesdependent
41. Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: Potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis
42. Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro
43. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum
44. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset
45. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Thl cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures
46. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity
47. Multiple myeloma: Increasing evidence for a multistep transformation process
48. Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis
49. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells
50. Modulation of hyperoxia-induced TNF-alpha expression in the newborn rat lung by thalidomide and dexamethasone
51. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity
52. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
53. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients
54. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: A single-institution study of 200 patients
55. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients
56. Plasma vascular endothelial but not fibroblast growth factor levels correlate with colorectal liver mestastasis vascularity and volume
57. Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma
58. Serum bFGF (basic fibroblast growth factor) and CA 15.3 in the monitoring of breast cancer patients
59. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis
60. Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy
61. Angiogenic factors in laryngeal carcinomas: Do they have prognostic relevance?
62. Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival
63. Immunomodulation by thalidomide and thalidomide analogues
64. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha